Ainos, Inc.

AI-generated fair value estimate for this company.

Method: Net financial position is negative (cash $1.4M vs total debt of $13.8M in convertible notes plus an ASE Inc loan, i.e. net debt of about $12.4M), so a standard DCF is meaningless on a company with TTM revenue of only $13,600. Used a probability-weighted scenario NPV instead: 70% probability of $0 equity value (failure/dilution wipeout), 25% probability of modest AI Nose/VELDONA commercial success worth about $55M equity in 5 years across an assumed 25M diluted shares discounted at 30%, and 5% probability of breakout success worth $300M equity across 40M diluted shares discounted at 30% for 5 years, divided across the current 7.38M shares outstanding.

Reasoning: Ainos is a going-concern-flagged pre-revenue AI-sensing/immunotherapy company (accumulated deficit $74.6M with a substantial doubt disclosure) whose entire equity value is optionality on future commercialization rather than existing cash flow so a risk-adjusted scenario approach fits better than a cash-flow DCF.